281 related articles for article (PubMed ID: 16098063)
1. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
Georgakis GV; Li Y; Humphreys R; Andreeff M; O'Brien S; Younes M; Carbone A; Albert V; Younes A
Br J Haematol; 2005 Aug; 130(4):501-10. PubMed ID: 16098063
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo.
Marini P; Denzinger S; Schiller D; Kauder S; Welz S; Humphreys R; Daniel PT; Jendrossek V; Budach W; Belka C
Oncogene; 2006 Aug; 25(37):5145-54. PubMed ID: 16636678
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
Smith MR; Jin F; Joshi I
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
[TBL] [Abstract][Full Text] [Related]
4. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
Shimada O; Wu X; Jin X; Nouh MA; Fiscella M; Albert V; Matsuda T; Kakehi Y
Urology; 2007 Feb; 69(2):395-401. PubMed ID: 17320696
[TBL] [Abstract][Full Text] [Related]
5. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma.
Younes M; Georgakis GV; Rahmani M; Beer D; Younes A
Eur J Cancer; 2006 Mar; 42(4):542-7. PubMed ID: 16426839
[TBL] [Abstract][Full Text] [Related]
6. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.
MacFarlane M; Kohlhaas SL; Sutcliffe MJ; Dyer MJ; Cohen GM
Cancer Res; 2005 Dec; 65(24):11265-70. PubMed ID: 16357130
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin.
Jin X; Wu XX; Abdel-Muneem Nouh MA; Kakehi Y
J Urol; 2007 May; 177(5):1894-9. PubMed ID: 17437844
[TBL] [Abstract][Full Text] [Related]
8. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression.
Wu XX; Jin XH; Zeng Y; El Hamed AM; Kakehi Y
Cancer Sci; 2007 Dec; 98(12):1969-76. PubMed ID: 17922852
[TBL] [Abstract][Full Text] [Related]
9. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
Nawrocki ST; Carew JS; Douglas L; Cleveland JL; Humphreys R; Houghton JA
Cancer Res; 2007 Jul; 67(14):6987-94. PubMed ID: 17638911
[TBL] [Abstract][Full Text] [Related]
11. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
Motoki K; Mori E; Matsumoto A; Thomas M; Tomura T; Humphreys R; Albert V; Muto M; Yoshida H; Aoki M; Tamada T; Kuroki R; Yoshida H; Ishida I; Ware CF; Kataoka S
Clin Cancer Res; 2005 Apr; 11(8):3126-35. PubMed ID: 15837769
[TBL] [Abstract][Full Text] [Related]
12. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
Sayers TJ; Murphy WJ
Cancer Immunol Immunother; 2006 Jan; 55(1):76-84. PubMed ID: 15864587
[TBL] [Abstract][Full Text] [Related]
13. Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L).
Guseva NV; Rokhlin OW; Taghiyev AF; Cohen MB
Breast Cancer Res Treat; 2008 Feb; 107(3):349-57. PubMed ID: 17453339
[TBL] [Abstract][Full Text] [Related]
14. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
15. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
16. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2.
Mori E; Thomas M; Motoki K; Nakazawa K; Tahara T; Tomizuka K; Ishida I; Kataoka S
Cell Death Differ; 2004 Feb; 11(2):203-7. PubMed ID: 14576771
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
Wu XX; Kakehi Y
Clin Cancer Res; 2009 Mar; 15(6):2039-47. PubMed ID: 19276256
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand.
Hasegawa H; Yamada Y; Harasawa H; Tsuji T; Murata K; Sugahara K; Tsuruda K; Ikeda S; Imaizumi Y; Tomonaga M; Masuda M; Takasu N; Kamihira S
Br J Haematol; 2005 Jan; 128(2):253-65. PubMed ID: 15638862
[TBL] [Abstract][Full Text] [Related]
19. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
[TBL] [Abstract][Full Text] [Related]
20. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]